These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22890603)

  • 21. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.
    Muhsen S; Moo TA; Patil S; Stempel M; Powell S; Morrow M; El-Tamer M
    Ann Surg Oncol; 2018 Jul; 25(7):1912-1920. PubMed ID: 29564588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
    Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
    Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumor and 1-3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases.
    Shen H; Zhao L; Wang L; Liu X; Liu X; Liu J; Niu F; Lv S; Niu Y
    Tumour Biol; 2016 May; 37(5):6465-75. PubMed ID: 26631044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
    Cheng SH; Horng CF; Clarke JL; Tsou MH; Tsai SY; Chen CM; Jian JJ; Liu MC; West M; Huang AT; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1401-9. PubMed ID: 16472935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
    Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
    Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Zhao JM; An Q; Sun CN; Li YB; Qin ZL; Guo H; Zeng X; Zhang YT; Wei LL; Han N; Sun SC; Zhang N
    Breast Cancer; 2021 Mar; 28(2):298-306. PubMed ID: 32940902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
    Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
    Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmastectomy radiotherapy reduces locoregional recurrence in elderly women with high-risk breast cancer.
    Lee JC; Truong PT; Kader HA; Speers CH; Olivotto IA
    Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):623-9. PubMed ID: 16372488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Number of negative lymph nodes can predict survival of breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy.
    Wu SG; Sun JY; Zhou J; Li FY; Zhou H; Lin Q; Lin HX; Bao Y; He ZY
    Radiat Oncol; 2014 Dec; 9():284. PubMed ID: 25511525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes.
    Moo TA; McMillan R; Lee M; Stempel M; Ho A; Patil S; El-Tamer M
    Ann Surg Oncol; 2014 May; 21(5):1569-74. PubMed ID: 24488216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
    Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
    Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
    [No Abstract]   [Full Text] [Related]  

  • 34. Is avoiding post-mastectomy radiotherapy justified for patients with four or more involved axillary nodes and endocrine-responsive tumours? Lessons from a series in a single institution.
    Gentilini O; Botteri E; Rotmensz N; Intra M; Gatti G; Silva L; Peradze N; Sahium RC; Gil LB; Luini A; Veronesi P; Galimberti V; Gandini S; Goldhirsh A; Veronesi U
    Ann Oncol; 2007 Aug; 18(8):1342-7. PubMed ID: 17693648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.
    Lanning RM; Morrow M; Riaz N; McArthur HL; Dang C; Moo TA; El-Tamer M; Krause K; Siu C; Hsu M; Zhang Z; Pei X; McCormick B; Powell SN; Ho A
    Ann Surg Oncol; 2015 Aug; 22(8):2517-25. PubMed ID: 25564167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence.
    Kuo SH; Huang CS; Kuo WH; Cheng AL; Chang KJ; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1456-64. PubMed ID: 18692329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
    Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of node-negative breast cancer 5 centimeters and larger treated with and without postmastectomy radiotherapy.
    Goulart J; Truong P; Woods R; Speers CH; Kennecke H; Nichol A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):758-64. PubMed ID: 20646860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
    Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
    Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.